Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Evolutionary Tree Capital Management LLC

Key Points

• Evolutionary Tree Capital Management LLC reduced its stake in Ascendis Pharma A/S by 31.4%, holding about $3.22 million worth of shares as of the latest SEC filing.
• Ascendis Pharma reported a quarterly earnings per share of ($1.66), missing estimates, but achieved $123.97 million in revenue, exceeding analyst expectations.
• Wall Street analysts have an average price target of $223.67 for Ascendis Pharma, with multiple firms issuing buy ratings and targets ranging up to $280.00.

Evolutionary Tree Capital Management LLC lessened its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,656 shares of the biotechnology company's stock after selling 9,459 shares during the quarter. Ascendis Pharma A/S makes up about 3.7% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 12th largest position. Evolutionary Tree Capital Management LLC's holdings in Ascendis Pharma A/S were worth $3,219,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ASND. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at $28,000. Quarry LP purchased a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $96,000. Tower Research Capital LLC TRC boosted its position in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth $174,000. Finally, Dearborn Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at about $203,000.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Morgan Stanley began coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $245.00 to $254.00 and gave the stock an "overweight" rating in a report on Tuesday, July 29th. Evercore ISI increased their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Finally, Royal Bank Of Canada lifted their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $223.67.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock traded down $3.99 during mid-day trading on Wednesday, reaching $182.60. 411,534 shares of the company were exchanged, compared to its average volume of 458,557. The business's 50 day simple moving average is $172.46 and its 200 day simple moving average is $157.82. The company has a market capitalization of $11.17 billion, a P/E ratio of -29.08 and a beta of 0.41. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $186.89.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.